PILA PHARMA AB (SE:PILA)

:PILA

PILA

PILA PHARMA AB

RESEARCH TOOLSreports

Want to see SE:PILA full AI Analyst Report?

PILA PHARMA AB (PILA) Price & Analysis

1 Followers

PILA Stock Chart & Stats

kr2.20

-kr0.50(-13.33%)

At close: Mar 06 4:00 PM EST

kr2.20

-kr0.50(-13.33%)

Day’s Range― - ―

52-Week Rangekr1.02 - kr3.93

Previous CloseN/A

Volume9.62K

Average Volume (3M)235.52K

Market Cap

kr63.27M

Enterprise Valuekr46.23M

Total Cash (Recent Filing)kr1.08M

Total Debt (Recent Filing)kr0.00

Price to Earnings (P/E)―

Beta0.81

Next Earnings

Aug 27, 2026

EPS Estimate

-0.22

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.42

Shares Outstanding45,682,120

10 Day Avg. Volume194,482

30 Day Avg. Volume235,519

Financial Highlights & Ratios

PEG Ratio-0.37

Price to Book (P/B)4.82

Price to Sales (P/S)63.25

P/FCF Ratio-7.76

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clean Balance SheetZero reported debt and a materially larger equity base provide durable financial flexibility for a cash‑consuming R&D-stage biotech. Lower leverage reduces bankruptcy risk, supports continued R&D spending, and improves the company’s ability to access non-debt financing over the next several quarters.

Focused Pipeline In Large MarketsA clear, focused R&D program concentrated on obesity and type 2 diabetes targets structurally large, growing markets with persistent unmet need. Concentration on a single mechanism (TRPV1) can allow efficient resource allocation and clearer clinical prioritization, a durable strategic advantage if clinical data progresses.

Improving Cash Flow TrendAlthough still negative, free cash flow improved year-over-year, indicating early progress in reducing net cash burn. A sustained trajectory of lower negative FCF would extend runway and reduce near-term financing frequency, improving strategic optionality for partnerships or staged financing over months.

Bears Say

Persistent Cash BurnConsistent negative operating and free cash flows signal ongoing dependence on external funding. Continued multi-year cash burn without commercial revenue increases dilution or financing risk, constrains R&D pacing, and can force program delays or asset sales if improvements don't continue.

Widening Net LossesGrowing annual net losses and persistently negative margins indicate limited operating leverage and escalating cash consumption. If losses widen, the equity base can erode, reducing solvency buffers and making it harder to finance pivotal trials or commercial preparations without significant dilution or partner deals.

No Commercial Revenue / Reliance On External FundingAs an R&D-stage company with no product revenues and no disclosed partner income, PILA is structurally dependent on equity raises or uncertain partnerships. This reliance increases dilution risk and ties program progress to capital markets or third‑party deal timing over the medium term.

PILA FAQ

What was PILA PHARMA AB’s price range in the past 12 months?

PILA PHARMA AB lowest stock price was kr1.02 and its highest was kr3.93 in the past 12 months.

What is PILA PHARMA AB’s market cap?

PILA PHARMA AB’s market cap is kr63.27M.

When is PILA PHARMA AB’s upcoming earnings report date?

PILA PHARMA AB’s upcoming earnings report date is Aug 27, 2026 which is in 67 days.

How were PILA PHARMA AB’s earnings last quarter?

PILA PHARMA AB released its earnings results on Feb 26, 2026. The company reported -kr0.369 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.369.

Is PILA PHARMA AB overvalued?

According to Wall Street analysts PILA PHARMA AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does PILA PHARMA AB pay dividends?

PILA PHARMA AB does not currently pay dividends.

What is PILA PHARMA AB’s EPS estimate?

PILA PHARMA AB’s EPS estimate is -0.22.

How many shares outstanding does PILA PHARMA AB have?

PILA PHARMA AB has 45,682,120 shares outstanding.

What happened to PILA PHARMA AB’s price movement after its last earnings report?

PILA PHARMA AB reported an EPS of -kr0.369 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.83%.

Which hedge fund is a major shareholder of PILA PHARMA AB?

Currently, no hedge funds are holding shares in SE:PILA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

PILA PHARMA AB

Based in Sweden, PILA PHARMA AB (publ) is a pharmaceutical firm actively engaged in clinical development. The company's principal drug, XEN-D0501, is a TRPV1 antagonist which has successfully completed two phase 2a clinical studies aimed at treating type 2 diabetes. PILA PHARMA AB (publ) was founded in 2014 and maintains its headquarters in Malmö, Sweden.